Covidien Launches Symbotex™ Composite Mesh for Surgical Laparoscopic and Open Ventral Hernia Repair

Innovative Mesh Designed to Simplify Surgeon Experience, Offer Patients Optimal Hernia Repairs

DUBLIN, Ireland--()--Further strengthening its broad line of hernia repair products, Covidien plc (NYSE: COV) today announced the U.S. launch of Symbotex™ composite mesh, an innovative product designed to make it easier for surgeons to perform surgical laparoscopic and open ventral hernia repairs.

A ventral hernia can develop when the outer layers of the abdominal wall weaken, bulge or tear, with most hernias resulting from strain on the abdominal muscles. Hernias can grow larger over time and cause serious complications if not surgically repaired.

“Through ongoing collaboration with our customers we know there is a need for a mesh that is easy to use and provides optimal repair for patients and we believe Symbotex provides the best of both worlds,” said Rob Claypoole, vice president and general manager, Hernia Care, Covidien. “With the addition of Symbotex, our hernia product line offers surgeons an even broader choice of unique solutions to address diverse patient needs.”

Symbotex composite mesh is dual sided, comprising a macroporous monofilament, hydrophilic textile in a three-dimensional construction that allows for reinforced strength, memory shape and significant tissue ingrowth. A bioabsorbable collagen film on the visceral side minimizes tissue attachments.

Symbotex mesh offers surgeons improved ease of use with an orientation marker that facilitates correctly placing the mesh over the hernia defect. Additionally, Symbotex mesh is transparent, offering improvements to the visualization of the anatomy during mesh placement and fixation. Symbotex composite mesh is available in a variety of shapes and sizes for laparoscopic and open ventral hernia repair.

The company announced the U.S. rollout at the American Hernia Society’s 16th Annual Hernia Repair meeting, taking place in Las Vegas, Nevada from March 13 through March 15.

In addition to Symbotex composite mesh, Covidien is showcasing the latest innovations to its portfolio of hernia repair products, including AccuMesh™ positioning system and ProGrip™ laparoscopic self-fixating mesh. For more information, please visit AHS Booth #500/502.

Symbotex composite mesh received 510(k) clearance from the U.S. Food and Drug Administration in August 2013.

ABOUT COVIDIEN

Covidien is a leading global health care products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien develops, manufactures and sells a diverse range of industry-leading medical device and supply products. With 2013 revenue of $10.2 billion, Covidien has more than 38,000 employees worldwide in more than 70 countries, and its products are sold in over 150 countries. Please visit www.covidien.com to learn more about our business.

Contacts

Covidien
John Jordan, 508-452-4891
Director
Communications
john.jordan@covidien.com
or
Coleman Lannum, CFA, 508-452-4343
Vice President
Investor Relations
cole.lannum@covidien.com
or
Marguerite Copel, 203-821-4720
Vice President
Communications
marguerite.copel@covidien.com
or
Todd Carpenter, 508-452-4363
Sr. Director
Investor Relations
todd.carpenter@covidien.com

Symbotex™ composite mesh for surgical laparoscopic and open ventral hernia repair is designed to offer patients optimal hernia repair performance. (Photo: Business Wire)

???news_view.multimedia.download???

???pagination.previous??? ???pagination.next???

Release Summary

Covidien launches Symbotex composite mesh, an innovative product designed to make it easier for surgeons to perform surgical laparoscopic and open ventral hernia repairs.

Sharing

Contacts

Covidien
John Jordan, 508-452-4891
Director
Communications
john.jordan@covidien.com
or
Coleman Lannum, CFA, 508-452-4343
Vice President
Investor Relations
cole.lannum@covidien.com
or
Marguerite Copel, 203-821-4720
Vice President
Communications
marguerite.copel@covidien.com
or
Todd Carpenter, 508-452-4363
Sr. Director
Investor Relations
todd.carpenter@covidien.com